Ioxitalamic acid

643.94

643.94

248-887-5

967RDI7Z6K

DTXSID60182457

V08AA05|V - Various

2924299090

116

2.34300

White solid

2.519g/cm3

253-255°C

582.8ºC at 760mmHg

306.3ºC

Soluble

-20°C Freezer

1.99E-14mmHg at 25°C

Ioxitalamate is reported to induce acute kidney injury. Preclinical studies showed that it does not present a teratogenic potential as well as a lack of effect on fertility. Ioxitalamate overdose may increase the risk of nephropathy and cardiovascular disorders.

Iodinated monomeric contrast agents are rarely bound to plasma proteins and when they bind, usually the association is very weak. When bound, it only represents from 0 to 27% of the ioxitalamate administered dose.

Ioxitalamate in both of its available forms is indicated for exploration of the digestive tract by tomodensitometry or by regular gastroduodenal radiography. Its use is restrained to the cases in which the administration of barium sulfate is not recommended or contraindicated. The intravascular administration of ioxitalamate is contraindicated as it may present significant side effects.

Ioxitalamate presents a very large osmolality which is related to the presence of renal toxicity, vasodilatation, bradycardia and pulmonary hypertension. This large osmolality allows ioxitalamate to move slowly in the bowel allowing for analysis for later follow excretion in the feces.

Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)

When administered ioxitalamate is not absorbed in the GI tract. In the case of presence of an intestinal perforation, ioxitalamate is completely absorbed. When administered intravascularly, ioxitalamate is rapidly distributed in the interstitial space and intravascular compartment.|As ioxitalamate is not absorbed in the normal intestine, the elimination route of this compound is entirely performed by the feces. When absorbed due to the presence of an intestinal perforation, ioxitalamate presents a rapid renal elimination. when ioxitalamate is administered intravascularly, it is eliminated unchanged mainly via renal excretion through glomerular filtration without reabsorption or tubular secretion. In the cases of renal failure, the elimination is mainly performed in the biliary, salivary, sudoral and colic route.|The volume of distribution of ioxitalamate is 194 ml/kg.|The total clearance rate of ioxitalamate is 120 ml/min.

The rapid clearance suggests that ioxitalamate is not metabolized in the body.

The elimination half-life of ioxitalamate is 1.1 hours.

Ioxitalamate acts as a bowel opacifier which facilitates the interpretation of the anatomy and differentiation of bowel loops from soft tissue masses.

5-acetamido-N-(2- hydroxyethyl)-2,4,6-triiodoisophthalamic acid